• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

    0.3370 +0.0004 (+0.12%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Apr 20, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,092,853
    Open 0.3281
    Bid (Size) 0.3200 (12,500)
    Ask (Size) 0.3370 (15,000)
    Prev. Close 0.3366
    Today's Range 0.3275 - 0.3400
    52wk Range 0.2000 - 3.050
    Shares Outstanding 584,908,239
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Regarding Their Rights
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire

    Performance

    YTD
    -34.0%
    -34.0%
    1 Month
    -1.6%
    -1.6%
    3 Month
    -40.4%
    -40.4%
    6 Month
    -85.0%
    -85.0%
    1 Year
    -85.5%
    -85.5%

    More News

    Read More
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    MREO Deadline: Rosen Law Firm Urges Mereo BioPharma Group plc (NASDAQ: MREO) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
    From Rosen Law Firm
    Via Business Wire
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    MREO UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    MREO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Berger Montague Advises Mereo BioPharma Group PLC (NASDAQ: MREO) Investors to Inquire About a Securities Fraud Class Action by April 6, 2026
    From Berger Montague
    Via GlobeNewswire
    News headline image
    MREO FINAL DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action – MREO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    MREO Investor Alert - Mereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    MEREO LAWSUIT DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Mereo BioPharma Stockholders with Large Losses to Contact the Firm Before April 6th
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
    From Mereo BioPharma Group plc
    Via GlobeNewswire
    News headline image
    MREO CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    ROSEN, A TOP RANKED LAW FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important Deadline in Securities Class Action – MREO
    From The Rosen Law Firm PA
    Via GlobeNewswire
    News headline image
    MREO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire

    Frequently Asked Questions

    Is Mereo BioPharma Group plc - American Depositary Shares publicly traded?
    Yes, Mereo BioPharma Group plc - American Depositary Shares is publicly traded.
    What exchange does Mereo BioPharma Group plc - American Depositary Shares trade on?
    Mereo BioPharma Group plc - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Mereo BioPharma Group plc - American Depositary Shares?
    The ticker symbol for Mereo BioPharma Group plc - American Depositary Shares is MREO on the Nasdaq Stock Market
    What is the current price of Mereo BioPharma Group plc - American Depositary Shares?
    The current price of Mereo BioPharma Group plc - American Depositary Shares is 0.3370
    When was Mereo BioPharma Group plc - American Depositary Shares last traded?
    The last trade of Mereo BioPharma Group plc - American Depositary Shares was at 04/20/26 04:00 PM ET
    What is the market capitalization of Mereo BioPharma Group plc - American Depositary Shares?
    The market capitalization of Mereo BioPharma Group plc - American Depositary Shares is 197.11M
    How many shares of Mereo BioPharma Group plc - American Depositary Shares are outstanding?
    Mereo BioPharma Group plc - American Depositary Shares has 197M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.